Ginkgo Bioworks Holdings DNA
NYSE DNA
$6.93 -0.02 (-0.29%)
As of: Sep 4, 2026 · 11:51 AM EDT

Ginkgo Bioworks Holdings (DNA) Income towards Parent Company (2020 - 2026)

Ginkgo Bioworks Holdings' (DNA) quarterly Income towards Parent Company came in at -$6.5 million in Q1 2026, up 14.63% YoY from -$5.7 million in Q1 2025, and up 91.92% on a QoQ basis from -$80.8 million in Q4 2025.

Analysis

Ginkgo Bioworks Holdings (DNA) Income towards Parent Company (2020 - 2026) Analysis & Trends

Ginkgo Bioworks Holdings (DNA) has 7 years of Income towards Parent Company data on file, last reported at -$6.5 million in Q1 2026.

  • Quarterly Income towards Parent Company rose 14.63% year-over-year to -$6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$228.3 million (up 41.27% YoY) and the FY2025 annual result came in at -$312.8 million, up 42.83% from the prior year.
  • Income towards Parent Company advanced to -$6.5 million in Q1 2026, from -$80.8 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of -$6.5 million in Q1 2026 to a low of -$670.6 million in Q2 2022.
  • A 5-year average of -$222.5 million and a median of -$173.1 million in 2022 frame the typical range for Income towards Parent Company.
  • Annual changes were most pronounced in 2022 — Income towards Parent Company tumbled 1131.22% — and 2025, when it soared 95.39%.
  • Tracing DNA's Income towards Parent Company over 5 years: stood at -$173.1 million in 2022, then fell by 22.31% to -$211.7 million in 2023, then surged by 49.2% to -$107.5 million in 2024, then gained by 24.91% to -$80.8 million in 2025, then surged by 91.92% to -$6.5 million in 2026.
  • The last three Income towards Parent Company figures came in at -$6.5 million (Q1 2026), -$80.8 million (Q4 2025), and -$80.8 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 140.21 Bn 132.36 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 86.04 Bn 78.05 Bn 3.93 Bn
3 Argenx Se 63.73 Bn 58.55 Bn 1.37 Bn
4 Moderna 57.59 Bn 52.46 Bn 52.00 Mn
5 Revolution Medicines 43.98 Bn 43.98 Bn -
6 BeOne Medicines 40.13 Bn 35.04 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.55 Bn 32.24 Bn 992.69 Mn
8 Royalty Pharma 28.60 Bn 27.77 Bn -
9 Insmed 27.70 Bn 26.54 Bn 358.27 Mn
10 Ginkgo Bioworks Holdings 430.31 Mn 345.78 Mn 18.44 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -46.71 Mn
Mar 31, 2026 -82.59 Mn
Dec 31, 2025 -80.75 Mn
Sep 30, 2025 -80.76 Mn
Jun 30, 2025 -60.30 Mn
Mar 31, 2025 -90.96 Mn
Dec 31, 2024 -107.53 Mn
Sep 30, 2024 -56.40 Mn
Jun 30, 2024 -217.18 Mn
Mar 31, 2024 -165.91 Mn
Dec 31, 2023 -211.69 Mn
Sep 30, 2023 -302.89 Mn
Jun 30, 2023 -173.32 Mn
Mar 31, 2023 -204.97 Mn
Dec 31, 2022 -173.08 Mn
Sep 30, 2022 -670.13 Mn
Jun 30, 2022 -670.57 Mn
Mar 31, 2022 -592.59 Mn
Dec 31, 2021 -1.60 Bn
Sep 30, 2021 -102.41 Mn